查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011177

生物製藥市場：2026-2032年全球市場預測（按產品類型、技術、給藥途徑、治療領域、最終用戶和分銷管道分類）

Biologics Market by Product Type, Technology, Route Of Administration, Therapeutic Area, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年生技藥品市場價值為4,594.5億美元，預計到2026年將成長至4,863.7億美元，複合年成長率為6.61%，到2032年將達到7,191.7億美元。

主要市場統計數據
基準年 2025 4594.5億美元
預計年份：2026年 4863.7億美元
預測年份 2032 7191.7億美元
複合年成長率 (%) 6.61%

對當前生物製藥市場趨勢進行簡潔且全面的概述，將科學創新、商業性挑戰和經營團隊重點聯繫起來。

生物製藥產業處於前沿科學與複雜商業性趨勢的交匯點，正在重塑多個治療領域的治療模式。本執行摘要為負責應對短期策略環境的高階領導者提供了清晰的敘述，整合了當前的結構性變化、監管和貿易壓力、細分市場帶來的機會以及區域性考量。它匯集了關於平台創新、生產和分銷管道以及相關人員期望的證據，使高階主管能夠明確投資、夥伴關係和營運調整的優先順序。

科學、監管和營運方面的整合進步如何重塑生物製藥開發、生產柔軟性和商業化策略。

生物製藥產業正經歷著一場變革性的轉型，其驅動力包括技術成熟、新的法規結構以及相關人員期望的轉變。基因編輯技術的進步和平台改進正將曾經的實驗性方法推向更具臨床可行性的領域，加速了人們對罕見疾病和複雜疾病治療方法的關注。同時，生產模式正朝著模組化和靈活的生產能力轉變，以縮短前置作業時間並提高對臨床需求的應對力，從而改變整個價值鏈中資本配置和合作決策的標準。

本研究評估了 2025 年關稅措施將如何影響生物製藥利害關係人供應鏈中的採購、區域產能確定和籌資策略。

2025年推出的最新關稅措施進一步增加了生物製藥產業相關人員的複雜性，影響到跨多個司法管轄區的採購、製造地位置以及整個供應鏈的成本結構。針對特定原料、設備或成品生物製藥的關稅迫使許多企業加快重新評估籌資策略，加強與本地供應商的關係，並採取雙重採購策略以降低風險。這些調整需要更精細的採購分析、重新談判供應商契約，以及與物流合作夥伴密切合作，以確保關鍵試劑和組件的持續供應。

透過整合細分洞察進行策略調整，將產品模式、底層技術、給藥途徑、治療領域、醫療保健環境和分銷方法連結起來。

細分市場分析揭示了產品類型、技術、給藥途徑、治療領域、終端用戶和分銷管道等方面的顯著趨勢，每種趨勢都需要獨特的策略應對措施。在產品類型方面，血液學因子、單株抗體、重組蛋白和疫苗等療法仍然是基礎生物製藥類別，擁有成熟的生產和監管路徑；而細胞療法和基因療法則正從專業機構向更廣泛的商業網路發展。特別是細胞療法，已細分為CAR-T療法和幹細胞療法，每種療法都有其獨特的研發路徑、生產限制和醫療服務模式，所有這些因素都會影響臨床應用策略。

區域需求和差異化策略，旨在協調不同全球醫療保健生態系統中的生產製造、監管合作和商業化。

區域趨勢正在創造獨特的機會和商業挑戰，這要求企業在市場准入、監管互動和生產力計畫採取差異化策略。在美洲，成熟的臨床生態系統和先進的製造群持續吸引對複雜治療方法和後期研發的投資，而政策對話和支付方結構正在影響商業化進程和證據要求。在該地區營運的企業通常會優先考慮可擴展的生產結構和完善的上市後證據策略，以適應複雜的醫療服務網路和報​​銷模式。

領先的生物製藥公司如何將夥伴關係、模組化製造和跨職能管治相結合，以確保具有競爭力的執行力和價值交付？

主要企業的生物製藥公司正透過策略夥伴關係、有針對性地投資產能以及專注於平台擴充性和合規應對力的產品組合開發，建立競爭優勢。那些將自身內部能力與外部合作夥伴（例如契約製造(CMO)、學術研究機構和利基技術提供者）進行策略整合的公司，更有能力應對複雜的研發流程，並加速從實驗室創新到臨床應用的轉化進程。投資於用於模組化生產和製程控制的先進分析技術，能夠提供差異化的營運能力，從而提高批次品質的可預測性並加速技術轉移。

為領導者提供可操作且優先的行動方案，以加強生物製藥產業的供應鏈、監管合規性、生產靈活性和商業化準備。

產業領導者應優先採取一系列具體行動，以管理風險、增強韌性、加速商業化並創造臨床價值。首先，將策略價值鏈評估納入企業規劃週期，評估採購集中度，並制定區域產能擴張和雙重採購的標準。其次，在臨床生命週期的早期階段，使產品開發藍圖與監管機構和支付方的證據要求保持一致，以減少下游摩擦，並實現更靈活的商業化路徑。第三，投資模組化製造平台和數位化流程控制，以縮短技術轉移週期，並支援高優先級療法的快速規模化生產。

採用多方面的調查方法，結合專家訪談、技術文獻分析和營運案例審查，制定實證策略指導。

本報告整合了來自一手和二手研究的成果，採用多維度的研究方法，結合定性專家訪談、技術文獻綜述和案例研究，得出可靠且基於證據的結論。報告訪問了研發、製造、監管事務和商業策略領域的專家，以了解他們對平台部署、生產力計畫和相關人員的第一手觀點。報告還查閱了二手技術文獻和監管指導文件，以檢驗機制和合獎勵的考量，並透過分析近期技術轉移和供應鏈重組案例研究，展示了實施過程中遇到的挑戰和解決方案的實際案例。

為了掌握生物製藥領域的創新機遇，我們整合了策略見解，強調了韌性、跨職能協調和能力投資的必要性。

生物製藥產業正處於一個十字路口，科學突破與複雜的商業性現實交織在一起，既蘊藏著巨大的潛力，也面臨日益成長的營運挑戰。那些積極應對供應鏈韌性、與監管機構和支付方合作、提升生產靈活性以及以細分市場主導的商業化的企業，將更有能力將科學進步轉化為對患者的切實影響和永續的商業成果。近期貿易和政策變化所帶來的累積影響凸顯了將地緣政治風險納入核心策略決策的必要性。同時，基因編輯和模組化生產等技術進步正在拓展可行的治療策略範圍。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥市場：依產品類型分類

  • 血液因子製劑
  • 細胞療法
    • CAR-T療法
    • 幹細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第9章：生物製藥市場：依技術分類

  • 細胞培養技術
  • 基因編輯技術
    • CRISPR
    • TALENs
    • 鋅指核酸酶
  • 融合瘤技術
  • 重組DNA技術

第10章：生物製藥市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 皮下

第11章：生物製藥市場：依治療領域分類

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學

第12章 生物製藥市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究機構

第13章 生物製藥市場：依通路分類

  • 醫院藥房
  • 線上管道
  • 零售藥房

第14章 生物製藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 生物製藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 生物製藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國生物藥學市場

第18章：中國生物製藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Catalent Inc.
  • Celltrion Inc.
  • CSL Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lonza Group AG
  • Merck & Co. Inc.
  • Moderna Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Samsung Biologics Co. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4302AC72200D

The Biologics Market was valued at USD 459.45 billion in 2025 and is projected to grow to USD 486.37 billion in 2026, with a CAGR of 6.61%, reaching USD 719.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 459.45 billion
Estimated Year [2026] USD 486.37 billion
Forecast Year [2032] USD 719.17 billion
CAGR (%) 6.61%

A concise, integrated overview of current biologics dynamics bridging scientific innovation, commercial pressure points, and operational priorities for leaders

Biologics sit at the intersection of advanced science and complex commercial dynamics, redefining treatment paradigms across multiple therapeutic areas. This executive summary synthesizes current structural shifts, regulatory and trade pressures, segmentation-driven opportunities, and regional considerations to provide a coherent narrative for senior leaders tasked with navigating the near-term strategic landscape. It brings together evidence on platform innovations, manufacturing and distribution vectors, and stakeholder expectations so that executives can prioritize investments, partnerships, and operational adjustments with clarity.

The narrative emphasizes the interplay between product innovation and the ecosystems required to deliver therapies at scale, from upstream R&D technologies through to downstream distribution channels. It highlights how changes in policy, supply chain resilience, and payer approaches are reshaping commercial pathways. By framing the key signals and practical implications, the introduction sets a foundation for reading subsequent sections as a connected set of insights intended to inform both high-level strategy and actionable initiatives within organizations active across biologics development, production, and delivery.

How convergent scientific, regulatory, and operational evolutions are reshaping biologics development, manufacturing flexibility, and commercialization strategies

The biologics landscape is undergoing transformative shifts driven by converging technological maturation, new regulatory frameworks, and evolving stakeholder expectations. Gene editing advancements and platform refinement have pushed previously experimental approaches into more clinically viable territories, accelerating interest in therapies that target rare and complex conditions. At the same time, manufacturing paradigms are shifting toward modular, flexible capacity to reduce lead times and increase responsiveness to clinical demand, altering capital allocation and partnership calculus across the value chain.

Policy and payer evolution are creating fresh incentives for outcome-based contracting and evidence generation, which in turn influence trial design, post-approval data commitments, and commercialization strategies. Digital tools and data interoperability are enhancing patient engagement and decentralized trial models, enabling more efficient recruitment and richer longitudinal evidence. Meanwhile, supply chain prioritization-spanning raw material sourcing, cold-chain logistics, and production redundancy-has become an operational imperative. These shifts collectively create both opportunities for differentiation and pressure to reconfigure traditional business models, encouraging organizations to adopt integrated cross-functional approaches that align R&D, manufacturing, regulatory affairs, and commercial planning.

Assessing how 2025 tariff measures have altered supply chain sourcing, regional capacity decisions, and procurement strategies for biologics stakeholders

Recent tariff actions instituted in 2025 introduced an additional layer of complexity for biologics stakeholders, affecting multi-jurisdictional procurement, manufacturing footprints, and cost structures across supply chains. Tariff measures that target specific inputs, equipment, or finished biologic products have prompted many organizations to reassess sourcing strategies, deepen local supplier relationships, and accelerate dual-sourcing initiatives to mitigate exposure. These adjustments have required more sophisticated procurement analytics, renegotiation of supplier contracts, and closer coordination with logistics partners to preserve continuity of critical reagent and component flows.

In response to tariff-driven uncertainties, manufacturers have also revisited capacity allocation decisions and capital investments, placing greater emphasis on regional production nodes that can serve priority markets with minimal cross-border friction. Regulatory authorities and industry groups have increasingly engaged in dialogue to clarify classification rules and to expedite customs procedures for temperature-sensitive shipments, which has eased some operational burdens. Simultaneously, payers and providers are attentive to potential downstream cost implications, prompting discussions about reimbursement frameworks and total-cost-of-care models that account for tariff effects. Ultimately, the cumulative impact of the 2025 tariff measures has elevated geopolitical considerations as a core element of strategic planning for biologics companies, influencing decisions from R&D site selection to commercialization sequencing and partnership structuring.

Integrated segmentation insights linking product modalities, enabling technologies, delivery pathways, therapeutic focuses, care settings, and distribution approaches for strategic alignment

Segment-level analysis reveals differentiated dynamics across product types, technologies, routes of administration, therapeutic areas, end users, and distribution channels, each demanding distinct strategic responses. Within product typologies, modalities such as blood factor products, monoclonal antibodies, recombinant proteins, and vaccines continue to represent foundational biologic classes with established manufacturing and regulatory pathways, while cell therapies and gene therapies are advancing from specialized centers toward broader commercial networks. Cell therapies specifically bifurcate into CAR-T therapies and stem cell therapies, each with unique development pathways, manufacturing constraints, and care-delivery models that affect clinical rollout strategies.

On the technology axis, the adoption and integration of cell culture platforms, hybridoma methods, and recombinant DNA approaches remain critical to optimizing yield and quality, whereas gene editing technology-comprising CRISPR, TALENs, and zinc finger nucleases-introduces powerful options for precision modalities but also raises new considerations around regulatory harmonization and long-term surveillance. Route-of-administration distinctions between intramuscular, intravenous, and subcutaneous delivery shape patient access strategies, cold-chain requirements, and site-of-care economics. Therapeutic area focus across autoimmune, cardiovascular diseases, infectious diseases, metabolic disorders, neurological disorders, and oncology directs clinical development prioritization and evidence generation pathways, while end users such as clinics, home healthcare services, hospitals, and research institutes determine distribution, training, and support models. Finally, distribution channel selection among hospital pharmacies, online channels, and retail pharmacies impacts fulfillment approaches, patient adherence initiatives, and the design of commercial partnerships. Taken together, these segmentation lenses provide a practical framework for aligning R&D investments, manufacturing design, and go-to-market models with the intrinsic needs of each therapeutic and delivery constellation.

Regional imperatives and differentiated strategies for aligning manufacturing, regulatory engagement, and commercialization across diverse global healthcare ecosystems

Regional dynamics are creating distinct opportunity contours and operational imperatives that require differentiated approaches to market entry, regulatory engagement, and capacity planning. In the Americas, established clinical ecosystems and advanced manufacturing clusters continue to attract investment in complex modalities and late-stage development, while policy dialogues and payer structures influence commercialization sequencing and evidence demands. Companies operating in this region frequently prioritize scalable manufacturing and robust post-market evidence strategies to align with sophisticated provider networks and reimbursement models.

Across Europe, the Middle East & Africa, stakeholders face a mix of mature regulatory frameworks in parts of Europe and capacity-constrained markets elsewhere, which encourages strategies that combine regional manufacturing hubs with tailored distribution partnerships. Regulatory harmonization efforts and shared procurement mechanisms can support wider access, but variations in infrastructure and pricing policies necessitate flexible commercial approaches. The Asia-Pacific region presents a highly heterogeneous set of conditions, with some markets offering rapid adoption pathways and growing clinical trial capacity while others focus on building manufacturing and regulatory capabilities. In many Asia-Pacific markets, favorable policy incentives and expanding healthcare demand are leading firms to accelerate technology transfer, local partnership formation, and regionally scaled production to serve both domestic and export opportunities. Across all regions, aligning manufacturing footprint, regulatory engagement, and commercialization models to local structural realities remains essential for success.

How leading biologics organizations are combining partnerships, modular manufacturing, and cross-functional governance to secure competitive execution and value delivery

Leading companies in the biologics space are consolidating their competitive positions through a blend of strategic partnerships, targeted capacity investments, and focused portfolio development that emphasizes platform scalability and regulatory readiness. Firms that strategically align their internal capabilities with external collaborators-such as CMOs, academic centers, and niche technology providers-are better positioned to manage development complexity and to accelerate translational pathways from laboratory innovations to clinical applications. Investment in modular manufacturing and advanced analytics for process control has become a distinguishing operational capability, enabling more predictable batch quality and faster tech transfer.

In parallel, successful organizations are proactively engaging regulators and payers to co-design evidence-generation strategies that demonstrate real-world value and to negotiate pathways for conditional approvals or managed-entry agreements where appropriate. Commercial sophistication is also rising, with leading players building comprehensive patient support ecosystems and innovative distribution arrangements to enhance uptake across hospitals, clinics, home care settings, and retail or online channels. Talent development and cross-functional governance structures that integrate R&D, manufacturing, regulatory affairs, and commercial teams are emerging as critical enablers for sustained execution in a landscape characterized by rapid technological change and evolving stakeholder expectations.

Practical and prioritized actions for leaders to strengthen supply chains, regulatory alignment, manufacturing agility, and commercial readiness in biologics

Industry leaders should prioritize a sequence of concrete actions designed to strengthen resilience, accelerate commercialization, and capture clinical value while managing risk. First, integrate strategic supply chain reviews into corporate planning cycles to assess sourcing concentration and to define criteria for regional capacity expansion and dual sourcing. Second, align product development roadmaps with regulatory and payer evidence requirements early in the clinical lifecycle to reduce downstream friction and to enable more flexible commercialization pathways. Third, invest in modular manufacturing platforms and digital process controls that reduce tech transfer timelines and support rapid scale-up for high-priority modalities.

In parallel, cultivate a disciplined partnership strategy that pairs internal strengths with external capabilities in advanced technologies, contract manufacturing, or specialized clinical networks, and formalize collaboration frameworks that include shared data standards and governance. Strengthen commercial models by designing distribution and patient-support programs tailored to route of administration and end-user settings, ensuring that hospital, clinic, home care, and pharmacy channels are each supported with appropriate clinical training and supply continuity measures. Finally, maintain an adaptive regulatory engagement posture to anticipate policy shifts and to participate in early dialogues on classification, approval pathways, and post-market obligations. Executing these prioritized steps will position organizations to respond more nimbly to geopolitical and technological disruptions while unlocking pathways to sustained clinical and commercial impact.

A multi-method research approach combining expert interviews, technical literature analysis, and operational case reviews to produce evidence-driven strategic guidance

This report synthesizes primary and secondary research inputs, structured around a multi-method approach that triangulates qualitative expert interviews, technical literature review, and operational case analysis to ensure robust, evidence-driven conclusions. Interviews were conducted with subject-matter experts across development, manufacturing, regulatory affairs, and commercial strategy to capture first-hand perspectives on platform adoption, capacity planning, and stakeholder incentives. Secondary technical literature and regulatory guidance documents were examined to validate mechanistic and compliance considerations, while operational case analyses of recent technology transfers and supply chain reconfigurations provided practical illustrations of execution challenges and mitigations.

Data synthesis emphasized reproducibility and traceability of sources, with analytic steps documented to support interpretation of thematic findings and implications. The methodology incorporated scenario-based sensitivity checks to test the resilience of strategic recommendations under differing policy and operational conditions. Throughout, the emphasis remained on translating empirical insights into actionable guidance for decision-makers, with transparency about evidence limitations and clear signposts for where further primary investigation would be valuable for organization-specific decisions.

Synthesis of strategic implications highlighting the need for resilience, cross-functional orchestration, and capability investments to capture biologics innovation

The biologics field is at an inflection point where scientific breakthroughs and complex commercial realities intersect, creating both significant promise and heightened operational demands. Organizations that proactively address supply chain resilience, regulatory and payer engagement, manufacturing agility, and segmentation-driven commercialization will be best positioned to translate scientific advances into patient impact and sustainable business outcomes. The cumulative effects of recent trade and policy shifts underscore the necessity of integrating geopolitical risk into core strategic decisions, while technology advances such as gene editing and modular manufacturing expand the palette of viable therapeutic strategies.

Moving forward, success will hinge on an organization's ability to orchestrate cross-functional capabilities, to form pragmatic partnerships, and to adopt evidence-centered commercialization models that reflect local regulatory and delivery contexts. Stakeholders should view the current environment as an opportunity to reconfigure traditional operating models and to invest in capabilities that support faster, more reliable delivery of complex biologics. By doing so, they can both mitigate short-term disruptions and position themselves to capture the long-term clinical and commercial benefits arising from the next wave of biologics innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Market, by Product Type

  • 8.1. Blood Factor Products
  • 8.2. Cell Therapies
    • 8.2.1. CAR-T Therapies
    • 8.2.2. Stem Cell Therapy
  • 8.3. Gene Therapies
  • 8.4. Monoclonal Antibodies
  • 8.5. Recombinant Proteins
  • 8.6. Vaccines

9. Biologics Market, by Technology

  • 9.1. Cell Culture Technology
  • 9.2. Gene Editing Technology
    • 9.2.1. CRISPR
    • 9.2.2. TALENs
    • 9.2.3. Zinc Finger Nucleases
  • 9.3. Hybridoma Technology
  • 9.4. Recombinant DNA Technology

10. Biologics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Biologics Market, by Therapeutic Area

  • 11.1. Autoimmune
  • 11.2. Cardiovascular Diseases
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Oncology

12. Biologics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Biologics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Channel
  • 13.3. Retail Pharmacy

14. Biologics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biologics Market

18. China Biologics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. Biogen Inc.
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Catalent Inc.
  • 19.13. Celltrion Inc.
  • 19.14. CSL Limited
  • 19.15. Eli Lilly and Company
  • 19.16. Gilead Sciences Inc.
  • 19.17. GlaxoSmithKline plc
  • 19.18. Johnson & Johnson
  • 19.19. Lonza Group AG
  • 19.20. Merck & Co. Inc.
  • 19.21. Moderna Inc.
  • 19.22. Novartis AG
  • 19.23. Novo Nordisk A/S
  • 19.24. Pfizer Inc.
  • 19.25. Roche Holding AG
  • 19.26. Samsung Biologics Co. Ltd.
  • 19.27. Sanofi SA
  • 19.28. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)